MARCO, traditionally recognized as a macrophage-specific receptor highly expressed on tumor-associated macrophages (TAMs) in various malignancies, including breast cancer, melanoma, pancreatic cancer, and hepatocellular carcinoma, has recently emerged as a molecule of interest in broader myeloid cell populations. This evidence concerns the gene MARCO and neoplasm.